Shares of Xencor Could Be Bought on a 50% Correction
- Oops!Something went wrong.Please try again later.
- XNCR
Xencor , with its protein engineering platform, is "developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and autoimmune disorders". In this daily bar chart of XNCR, below, we can see that prices quickly rebounded in June after a decline from early January. XNCR is in "striking distance" of the 200-day line now.